Integrated sample inactivation, amplification, and Cas13-based detection of SARS-CoV-2. Author Jon Arizti-Sanz, Catherine Freije, Alexandra Stanton, Chloe Boehm, Brittany Petros, Sameed Siddiqui, Bennett Shaw, Gordon Adams, Tinna-Solveig Kosoko-Thoroddsen, Molly Kemball, Robin Gross, Loni Wronka, Katie Caviness, Lisa Hensley, Nicholas Bergman, Bronwyn MacInnis, Jacob Lemieux, Pardis Sabeti, Cameron Myhrvold Publication Year 2020 Type Journal Article Abstract The COVID-19 pandemic has highlighted that new diagnostic technologies are essential for controlling disease transmission. Here, we develop SHINE (SHERLOCK and HUDSON Integration to Navigate Epidemics), a sensitive and specific integrated diagnostic tool that can detect SARS-CoV-2 RNA from unextracted samples. We combine the steps of SHERLOCK into a single-step reaction and optimize HUDSON to accelerate viral inactivation in nasopharyngeal swabs and saliva. SHINE's results can be visualized with an in-tube fluorescent readout - reducing contamination risk as amplification reaction tubes remain sealed - and interpreted by a companion smartphone application. We validate SHINE on 50 nasopharyngeal patient samples, demonstrating 90% sensitivity and 100% specificity compared to RT-PCR with a sample-to-answer time of 50 minutes. SHINE has the potential to be used outside of hospitals and clinical laboratories, greatly enhancing diagnostic capabilities. Journal bioRxiv Date Published 2020 May 28 DOI 10.1101/2020.05.28.119131 Alternate Journal bioRxiv PMCID PMC7265687 PMID 32511415 PubMedPubMed CentralGoogle ScholarBibTeXEndNote X3 XML